Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 confirmatory trial of TAK-536 vs candesartan in essential hypertension
jRCT2080220734Phase 3
- Sponsor
- Takeda
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of azilsartan in essential hypertension (2 arms), sponsored by Takeda.
02
Drugs
azilsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080220734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220734.